Short WR, Tunkel AR
Department of Medicine, Medical College of Pennsylvania/Hahnemann University, 3300 Henry Avenue, Philadelphia, PA 19129, USA.
Curr Infect Dis Rep. 2000 Aug;2(4):327-331. doi: 10.1007/s11908-000-0011-2.
Bacterial meningitis is an important cause of morbidity and mortality in the United States and throughout the world. Over the past 20 years, there have been significant changes in the epidemiology of bacterial meningitis. The most important change is the decrease in the frequency of Haemophilus influenzae type b as the most common etiologic agent of bacterial meningitis, since the H. influenzae type b conjugate vaccine was introduced. Streptococcccus pneumoniae is now the major cause of bacterial meningitis in the US and bacterial meningitis is now a disease predominantly of adults, rather than of infants and children. Emergence of antimicrobial resistance in S. pneumoniae has also altered the approach to antimicrobial therapy in patients with pneumococcal meningitis, indicating the need to use preventive strategies to reduce the frequency of this serious infection. Recent licensure of the heptavalent pneumococcal conjugate vaccine will likely decrease the overall incidence of pneumococcal meningitis.
在美国及全球范围内,细菌性脑膜炎是发病和死亡的重要原因。在过去20年里,细菌性脑膜炎的流行病学发生了显著变化。最重要的变化是,自引入b型流感嗜血杆菌结合疫苗后,b型流感嗜血杆菌作为细菌性脑膜炎最常见病原体的频率有所下降。目前,肺炎链球菌是美国细菌性脑膜炎的主要病因,而且细菌性脑膜炎如今主要是成人疾病,而非婴幼儿疾病。肺炎链球菌中抗菌药物耐药性的出现也改变了肺炎球菌性脑膜炎患者的抗菌治疗方法,这表明需要采用预防策略来降低这种严重感染的发生率。七价肺炎球菌结合疫苗最近获得许可,可能会降低肺炎球菌性脑膜炎的总体发病率。